Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

ZaBeCor Pharmaceuticals announces that the United States Food and Drug Administration ("FDA") has approved the Company's Investigational New Drug Application ("IND") for the treatment of asthma. This approval enables the Company to proceed with Phase I clinical trials in humans for its asthma drug candidate, Excellair. The IND review included ZaBeCor's clinical development plan, Phase I clinical trial protocols, manufacturing plans and extensive pre-clinical studies.

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address